RecruitingNot applicableNCT07479056

Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy

Studying Acrocallosal syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
SUK MIN SEO
Principal Investigator
Suk Seo, MD, PhD
The Catholic University of Korea Eunpyeong St. Mary's Hospital
Intervention
Fexuprazan 40mg(drug)
Enrollment
400 target
Eligibility
20 years · All sexes
Timeline
2024 – 2028

Study locations (1)

Collaborators

Daewoong Pharmaceutical Co. LTD.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07479056 on ClinicalTrials.gov

Other trials for Acrocallosal syndrome

Additional recruiting or active studies for the same condition.

See all trials for Acrocallosal syndrome →

← Back to all trials